SAB Biotherapeutics (NASDAQ:SABS) Stock Rating Upgraded by Wall Street Zen

SAB Biotherapeutics (NASDAQ:SABS) was upgraded by equities research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report issued on Monday.

SABS has been the topic of a number of other reports. Jefferies Financial Group began coverage on SAB Biotherapeutics in a research note on Wednesday, May 20th. They set a “buy” rating and a $11.00 price target on the stock. Chardan Capital lifted their price objective on SAB Biotherapeutics from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Wednesday, June 17th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of SAB Biotherapeutics in a report on Monday, June 15th. Rodman & Renshaw reissued a “buy” rating and set a $13.00 target price on shares of SAB Biotherapeutics in a research note on Monday, May 11th. Finally, Zacks Research raised SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, May 11th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $12.00.

SAB Biotherapeutics Stock Performance

Shares of SABS stock opened at $3.76 on Monday. The firm’s 50 day moving average price is $3.70 and its 200-day moving average price is $3.83. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.22 and a current ratio of 9.22. SAB Biotherapeutics has a one year low of $1.85 and a one year high of $5.15. The firm has a market cap of $342.12 million, a P/E ratio of -2.89 and a beta of 0.53.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.28) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.28). As a group, equities research analysts predict that SAB Biotherapeutics will post -1.21 EPS for the current year.

Institutional Trading of SAB Biotherapeutics

Several hedge funds have recently modified their holdings of SABS. PNC Financial Services Group Inc. purchased a new stake in SAB Biotherapeutics during the 1st quarter worth about $29,000. ADAR1 Capital Management LLC purchased a new position in shares of SAB Biotherapeutics in the 3rd quarter valued at about $30,000. Dimensional Fund Advisors LP purchased a new position in shares of SAB Biotherapeutics in the 3rd quarter valued at about $32,000. State of Wyoming acquired a new position in shares of SAB Biotherapeutics during the fourth quarter worth about $34,000. Finally, Virtu Financial LLC acquired a new position in shares of SAB Biotherapeutics during the third quarter worth about $40,000. 7.82% of the stock is currently owned by institutional investors and hedge funds.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.